A Phase 1/2 interventional study of Neoantigen specific TCR-T cell drug product and Aldesleukin (IL-2) in Gynecologic Cancer, Colorectal Cancer and Pancreatic Cancer, sponsored by Alaunos Therapeutics. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Alaunos Therapeutics · Phase 1/2, Interventional, and Treatment
Sponsor halted enrollment on 14 Aug 2023 for business reasons after a Board review of funding needs and permanently discontinued TCR-T cell manufacturing. The study was not stopped for safety reasons.
Morelli MP, Negrao MV, Collinson-Pautz MR, et al. Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by soli…
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,342 studies in Colorectal Neoplasms with a site in United States — 415 open to participants now, 629 under way, 30 of them phase 3. Colorectal Neoplasms · United States.
Among the 2,342 studies in Colorectal Neoplasms with a site in United States, this one is the 1,764th largest by enrollment of the 1,934 interventional ones that give a count, is one of 127 that started in 2022, is one of 267 in phase 1/2, and was the 1,701st registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →415 of the 2,342 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
Exelixis · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 40–80 · Men only
Incyte Corporation · Sites in United States, Puerto Rico
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,342 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 818 · Phase 2 793 · Phase 3 132 · Phase 4 19
First in 1981; this study’s year is marked. 127 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 64 across the 1,934 interventional studies, 220 across the 325 observational. Of the 1,566 that completed or were terminated, 551 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
887 of 2,342 have an industry lead sponsor. The 10 most frequent:
Alaunos Therapeutics is the lead sponsor of 37 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Alaunos Therapeutics has 2 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
226 of the studies in Colorectal Neoplasms with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05141721Phase 3Seattle Project CorporationA Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer | 2027-03 |
| NCT04428905Phase 3City of Hope Medical CenterSelf-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer | 2027-03-31 |
| NCT02997228Phase 3National Cancer Institute (NCI)Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study | 2027-06-01 |
| NCT01349881Phase 3SWOG Cancer Research NetworkS0820, Adenoma and Second Primary Prevention Trial | 2027-09-15 |
| NCT03796884Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityLinaclotide in Treating Patients With Stages 0-3 Colorectal Cancer | 2026-11 |
Add all 226 to your calendar (.ics) → With an account.
Among the 2,342 studies in Colorectal Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors. The study ended during Phase I Arm A after 8 subjects were treated. Arm B and Phase II were not initiated, and the maximum tolerated dose or recommended Phase II dose was not determined.
A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors.
Screening was initially conducted under TCR001-002. TCR001-201 Protocol Amendment 4, approved by the IRB on 20 January 2023 and implemented at the site in February 2023, incorporated HLA typing and tumor neoantigen screening into TCR001-201. Eligibility required a matching tumor mutation and HLA restriction represented in the Sponsor's clinical TCR library.
The Phase I part of this study is a prospective, open-label, dose-escalation study of TCR-T cell drug product in patients with progressive or recurrent solid tumors who have failed standard therapy. The Phase II part is a prospective, open-label, single dose portion of the study. The planned Phase II portion was to begin after determination of the maximum tolerated dose or recommended Phase II dose in Phase I. The program closed during Phase I Arm A before that determination. Arm B and Phase II were not initiated, and no subject received interleukin-2 under this study.
Subjects with one of the following histologically confirmed solid tumors will be included:
Subject must have a tumor mutation and HLA typing combination that matches to at least one of the following TCRs in the Alaunos' library (mutation \& HLA type):
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who have previously received at least one line of standard systemic therapy for their advanced/ cancer and have either progressed, recurred, or were intolerant to the previous treatment. Specifically:
Subgroup 1. Gynecologic cancers (i.e., ovarian or endometrial):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase I: Dose-escalation of TCR-T Cell Drug Product Phase II: Single dose of TCR-T Cell Drug Product after MTD/RP2D determine in Phase I portion of the study
Biological: Neoantigen specific TCR-T cell drug product
Phase I: Dose-escalation of TCR-T Cell Drug Product with Aldesleukin (IL-2) Phase II: Single dose of TCR-T Cell Drug Product with Aldesleukin (IL-2) after MTD/RP2D determine in Phase I portion of the study
Biological: Neoantigen specific TCR-T cell drug product · Biological: Aldesleukin (IL-2)
Phase I: Ascending dose, single Infusion of TCR+ Cells Phase II: Single infusion at the RP2D
To support growth and activation of TCR-T cell drug product
Number of Participants With Treatment-Emergent Adverse Events
Treatment-emergent adverse events (TEAEs) were defined as any adverse event that began or worsened after initiation of lymphodepletion and up to 28 days following TCR-T cell infusion. TEAEs were coded using MedDRA and summarized by system organ class and preferred term, severity, and relationship to study treatment. Participants were followed for delayed or ongoing toxicities for up to 1 year.
Time frame: From initiation of lymphodepletion through Day 28 after TCR-T cell infusion, and through long-term follow-up for up to 1 year.
Frequency of Dose Limiting Toxicities
Number of participants experiencing DLTs, defined as specific adverse events attributable to the TCR-T cell drug product occurring within the first 28 days of infusion. DLTs include, but are not limited to, Grade 4 neutropenia lasting ≥ 14 days, Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with significant bleeding, and ≥ Grade 3 febrile neutropenia with hemodynamic compromise. Non-hematologic DLTs include Grade 3 or 4 Cytokine Release Syndrome (CRS) that does not improve to Grade ≤ 2 within 72 hours, and Grade 3 Immune-effector cell-associated neurotoxicity syndrome (ICANS) that does not resolve to Grade ≤ 2 within 7 days, among others. The severity of adverse events will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.
Time frame: From Day 0 to Day 28 post TCR-T cell drug product infusion.
Determination of Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D)
MTD/RP2D determination was planned using accelerated escalation followed by the Bayesian Optimal Interval (BOIN) design and the protocol dose-escalation, de-escalation and stopping rules. Overt-toxicity criteria included 2 or more DLTs and consideration of longer-term toxicity. The trial would stop if the lowest dose was eliminated for overt toxicity. Formal MTD/RP2D determination was not completed because the study closed during Phase I Arm A.
Time frame: From Day 0 to Day 28 post TCR-T cell drug product infusion.
Feasibility of TCR-T Cell Drug Product Manufacturing
Number of participants in each mutually exclusive leukapheresis and manufacturing disposition category. A full-scale run is a clinical drug-product manufacturing run; small-scale testing and cell enrichment or cryopreservation are not full-scale runs. All released products were infused. Final cell count and viability of released products are reported in separate outcome measures.
Time frame: From apheresis collection to the release of the final TCR-T cell drug product for infusion, estimated to be approximately 5 weeks
TCR-T Cell Persistence
Peripheral-blood TCR-T vector copy number (VCN) was measured by droplet digital PCR (ddPCR; LabCorp Drug Development) in copies per 1 × 10⁶ cells. Visits are nominal. One DL2 participant's nominal Day 28 and Week 6 samples were both collected on Day 44; the Month 18 sample was collected on Day 577. Samples after TCR001-201 exit were collected under TCR001-202 (NCT05292859). Summaries include quantifiable values only; not-detected and below-LLOQ values are excluded. NA indicates no quantifiable result. One post-dose Day 0 sample has identical copies/reaction and copies/mL values to another participant's sample; the copies per 1 × 10⁶ cells values differ. Sampling ended at disease progression, death or program closure.
Time frame: Baseline through nominal Month 18 post-infusion.
Percent Change in TCR-T Cell Count From Post Dose to Day 28
For each participant, percent change from the highest post-dose VCN (copies per 1 × 10⁶ cells, ddPCR) from Day 0 post-dose through Day 21 to the nominal Day 28 value: ((Day 28 - peak) / peak) × 100. A Day 28 value below the LLOQ was set to 0 (-100%).
Time frame: Post-dose Day 0 through nominal Day 28; nominal Day 28 samples were collected on actual Days 27 to 44.
Final T-Cell Count in Released TCR-T Cell Drug Product
Final cell counts from the Certificate of Analysis for the released product administered to each participant. The two rows report total viable cells from the automated cell counter and final murine T-cell receptor-positive (mTCR+) cells from the Content-Calculation method, each in billions of cells. These are manufacturing results, not the administered dose. For participants with more than 1 manufacturing run, only the released lot is used.
Time frame: At release testing of the final infused lot before TCR-T cell infusion on Day 0; the lot was harvested 1 day before infusion (fresh product, 3 participants) or 30 to 156 days before infusion (cryopreserved product, 5 participants).
Viability of Released TCR-T Cell Drug Product
Percent viability reported on the final Certificate of Analysis for the released TCR-T cell product administered to each participant. One released product per participant is summarized, including the second manufacturing run when that run supplied the infused product.
Time frame: At release testing of the final infused lot before TCR-T cell infusion on Day 0; the lot was harvested 1 day before infusion (fresh product, 3 participants) or 30 to 156 days before infusion (cryopreserved product, 5 participants).
Protocol-Defined Duration of TCR-T Cell Persistence to the Last Quantifiable VCN Sample
Per Protocol Section 15.3.4 and SAP Section 4.5.2, duration is the number of days from infusion (Day 0) to the last sample with VCN at or above the assay lower limit of quantification. This is an observed last-quantifiable-sample metric. Sampling stopped at different times because of disease progression, death or program closure, so it does not establish when TCR-T cells disappeared. Later ND or below-LLOQ samples do not extend this metric. Samples from TCR001-202 are included where applicable.
Time frame: From infusion through available VCN follow-up to nominal Month 18; last quantifiable samples were on Days 21 to 180.
34 participants signed consent forms, 14 participants were apheresed, and 8 participants were lymphodepleted and per the protocol definition were considered enrolled. 8 were treated with TCR-T cells.
| Milestone | Assigned Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹ ) | Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹) | Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹) |
|---|---|---|---|
| Started | 1 | 13 | 0 |
| Apheresis 1 | 1 | 13 | 0 |
| Apheresis 2 | 0 | 2 | 0 |
| Manufacture 1 | 1 | 10 | 0 |
| Manufacture 2 | 0 | 2 | 0 |
| Lymphodepletion (enrollment) | 1 | 7 | 0 |
| Tcr infusion | 1 | 7 | 0 |
| Assigned dose level 2 but received dose level 1 due to manufacturing process | 0 | 2 | 0 |
| Completed | 1 | 7 | 0 |
| Not completed | 0 | 6 | 0 |
| Withdrew: Apheresed but not administered tcr-t cells due to manufacturing failure | 0 | 2 | 0 |
| Withdrew: Apheresed but not administered tcr-t cells due to participant developed brain metastases | 0 | 1 | 0 |
| Withdrew: Apheresed but not administered tcr-t cells due to early termination of study | 0 | 2 | 0 |
| Withdrew: Apheresed but not administered tcr-t cells due to participant cerebrovascular accident | 0 | 1 | 0 |
Treatment-emergent adverse events (TEAEs) were defined as any adverse event that began or worsened after initiation of lymphodepletion and up to 28 days following TCR-T cell infusion. TEAEs were coded using MedDRA and summarized by system organ class and preferred term, severity, and relationship to study treatment. Participants were followed for delayed or ongoing toxicities for up to 1 year.
| participants | Assigned Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹) | Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹) | Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹) |
|---|---|---|---|
| Any TEAE | 1 | 7 | — |
| Drug-related TEAE | 1 | 7 | — |
| Drug-related Grade 3 or higher TEAE | 1 | 6 | — |
| TEAE leading to death | 0 | 0 | — |
| Treatment-emergent SAE | 1 | 2 | — |
Number of participants experiencing DLTs, defined as specific adverse events attributable to the TCR-T cell drug product occurring within the first 28 days of infusion. DLTs include, but are not limited to, Grade 4 neutropenia lasting ≥ 14 days, Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with significant bleeding, and ≥ Grade 3 febrile neutropenia with hemodynamic compromise. Non-hematologic DLTs include Grade 3 or 4 Cytokine Release Syndrome (CRS) that does not improve to Grade ≤ 2 within 72 hours, and Grade 3 Immune-effector cell-associated neurotoxicity syndrome (ICANS) that does not resolve to Grade ≤ 2 within 7 days, among others. The severity of adverse events will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.
| Participants | Assigned Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹) | Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹) | Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹) |
|---|---|---|---|
| Frequency of Dose Limiting Toxicities | 0 | 0 | — |
MTD/RP2D determination was planned using accelerated escalation followed by the Bayesian Optimal Interval (BOIN) design and the protocol dose-escalation, de-escalation and stopping rules. Overt-toxicity criteria included 2 or more DLTs and consideration of longer-term toxicity. The trial would stop if the lowest dose was eliminated for overt toxicity. Formal MTD/RP2D determination was not completed because the study closed during Phase I Arm A.
| Dose level of TCR-T cells infused | All Dose Levels (DLT-Evaluable Population) |
|---|---|
| Determination of Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D) | NA |
Number of participants in each mutually exclusive leukapheresis and manufacturing disposition category. A full-scale run is a clinical drug-product manufacturing run; small-scale testing and cell enrichment or cryopreservation are not full-scale runs. All released products were infused. Final cell count and viability of released products are reported in separate outcome measures.
| participants | Apheresed Participants (Feasibility Population) |
|---|---|
| Unable to be apheresed for logistical or medical reasons | 0 |
| Apheresis performed but manufacturing not initiated due to study closure. | 2 |
| Infused successfully at the planned dose after 1 manufacturing round. | 6 |
| Infused at a lower dose than planned after 1 manufacturing round. | 1 |
| Infused at a lower dose than planned after 2 manufacturing rounds. | 1 |
| Participants who were manufacturing failures after 2 manufacturing rounds | 1 |
| Manufacturing failure after 1 manufacturing round; not infused | 1 |
| Insufficient cell yield after 1 manufacturing round and new brain metastases; not infused | 1 |
| Low expansion on small-scale testing and stroke after leukapheresis; not infused | 1 |
Peripheral-blood TCR-T vector copy number (VCN) was measured by droplet digital PCR (ddPCR; LabCorp Drug Development) in copies per 1 × 10⁶ cells. Visits are nominal. One DL2 participant's nominal Day 28 and Week 6 samples were both collected on Day 44; the Month 18 sample was collected on Day 577. Samples after TCR001-201 exit were collected under TCR001-202 (NCT05292859). Summaries include quantifiable values only; not-detected and below-LLOQ values are excluded. NA indicates no quantifiable result. One post-dose Day 0 sample has identical copies/reaction and copies/mL values to another participant's sample; the copies per 1 × 10⁶ cells values differ. Sampling ended at disease progression, death or program closure.
| copies/1x10^6 cells | Assigned Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹) | Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹) | Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹) |
|---|---|---|---|
| Baseline (1 week prior to infusion) | NA | NA (0 to 0) | — |
| Predose Day 0 | NA | NA (0 to 0) | — |
| Post Dose Day 0 | 4,240,000 | 2,570,000 (779,000 to 3,970,000) | — |
| Day 1 | 3,190,000 | 373,000 (20,700 to 1,710,000) | — |
| Day 2 | 2,640,000 | 804,000 (61,400 to 2,270,000) | — |
| Day 4 | 3,500,000 | 570,000 (18,700 to 3,400,000) | — |
| Day 7 | 743,000 | 101,000 (5,320 to 3,730,000) | — |
| Day 10 | 674,000 | 112,000 (14,200 to 961,000) | — |
| Day 14 | 984,000 | 112,000 (7,900 to 938,000) | — |
| Day 21 | 504,000 | 41,300 (1,140 to 489,000) | — |
| Day 28 | 404,000 | 90,000 (5,450 to 297,000) | — |
| Week 6 | 197,000 | 35,600 (3,330 to 203,000) | — |
| Week 12 | 163,000 | 27,200 (1,960 to 121,000) | — |
| Month 3 | — | 42,400 | — |
| Month 6 | 88,100 | 8,120 | — |
| Month 15 | — | NA | — |
| Month 18 | — | NA | — |
For each participant, percent change from the highest post-dose VCN (copies per 1 × 10⁶ cells, ddPCR) from Day 0 post-dose through Day 21 to the nominal Day 28 value: ((Day 28 - peak) / peak) × 100. A Day 28 value below the LLOQ was set to 0 (-100%).
| percent change from peak post dose | Assigned Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹) | Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹) | Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹) |
|---|---|---|---|
| Percent Change in TCR-T Cell Count From Post Dose to Day 28 | -90.5 | -96.0 (-100 to -91.1) | — |
Final cell counts from the Certificate of Analysis for the released product administered to each participant. The two rows report total viable cells from the automated cell counter and final murine T-cell receptor-positive (mTCR+) cells from the Content-Calculation method, each in billions of cells. These are manufacturing results, not the administered dose. For participants with more than 1 manufacturing run, only the released lot is used.
| 10^9 cells | Assigned Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹ ) | Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹) | Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹) |
|---|---|---|---|
| Total viable cells | 10.0 | 25.0 (1.4 to 69.2) | — |
| Final mTCR-positive cells | 9.0 | 20.7 (1.0 to 64.0) | — |
Percent viability reported on the final Certificate of Analysis for the released TCR-T cell product administered to each participant. One released product per participant is summarized, including the second manufacturing run when that run supplied the infused product.
| Percent viable cells | Assigned Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹ ) | Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹) | Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹) |
|---|---|---|---|
| Viability of Released TCR-T Cell Drug Product | 95.1 | 87.3 (76.7 to 92.8) | — |
Per Protocol Section 15.3.4 and SAP Section 4.5.2, duration is the number of days from infusion (Day 0) to the last sample with VCN at or above the assay lower limit of quantification. This is an observed last-quantifiable-sample metric. Sampling stopped at different times because of disease progression, death or program closure, so it does not establish when TCR-T cells disappeared. Later ND or below-LLOQ samples do not extend this metric. Samples from TCR001-202 are included where applicable.
| Days | Assigned Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹ ) | Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹) | Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹) |
|---|---|---|---|
| Protocol-Defined Duration of TCR-T Cell Persistence to the Last Quantifiable VCN Sample | 172 | 86 (21 to 180) | — |
Collected over From initiation of lymphodepletion until the participant's final study visit, up to approximately 1 year after TCR-T cell infusion.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Assigned Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹) | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) |
| Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹) | 6/7 (85.7%) | 2/7 (28.6%) | 7/7 (100%) |
| Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹) | — | — | — |
| Event | Assigned Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹) | Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹) | Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹) |
|---|---|---|---|
| Cytokine release syndromeImmune system disorders | 1/1 | 2/7 | — |
| HypotensionVascular disorders | 1/1 | 0/7 | — |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/1 | 0/7 | — |
| Sinus tachycardiaCardiac disorders | 1/1 | 0/7 | — |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/1 | 0/7 | — |
| AnaemiaBlood and lymphatic system disorders | 1/1 | 0/7 | — |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/1 | 0/7 | — |
| Event | Assigned Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹) | Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹) | Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹) |
|---|---|---|---|
| Abdominal distensionGastrointestinal disorders | 1/1 | 0/7 | — |
| Activated partial thromboplastin time prolongedInvestigations | 1/1 | 4/7 | — |
| Alanine aminotransferase increasedInvestigations | 1/1 | 4/7 | — |
| AnaemiaBlood and lymphatic system disorders | 1/1 | 7/7 | — |
| Aspartate aminotransferase increasedInvestigations | 1/1 | 2/7 | — |
| Blood fibrinogen increasedInvestigations | 1/1 | 2/7 | — |
| ChillsGeneral disorders | 1/1 | 3/7 | — |
| ConstipationGastrointestinal disorders | 1/1 | 2/7 | — |
| CoughRespiratory, thoracic and mediastinal disorders | 1/1 | 3/7 | — |
| COVID-19Infections and infestations | 1/1 | 0/7 | — |
Safety Analysis Set: all 8 participants who received lymphodepletion and a TCR-T cell infusion. The 6 participants who underwent leukapheresis but were not enrolled or infused are not included.
| Age, Continuous(years) | Assigned to Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹) | Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹) | Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹) | Total |
|---|---|---|---|---|
| Median | 34 | 53 (50 to 65) | — | 53 (34 to 65) |
| Sex: Female, Male(Participants) | Assigned to Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹) | Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹) | Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹) | Total |
|---|---|---|---|---|
| Female | 1 | 4 | 0 | 5 |
| Male | 0 | 3 | 0 | 3 |
| Ethnicity (NIH/OMB)(Participants) | Assigned to Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹) | Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹) | Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | — | 1 |
| Not Hispanic or Latino | 0 | 7 | — | 7 |
| Unknown or Not Reported | 0 | 0 | — | 0 |
| Race (NIH/OMB)(Participants) | Assigned to Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹) | Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹) | Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | — | 0 |
| Asian | 0 | 1 | — | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | — | 0 |
| Black or African American | 0 | 0 | — | 0 |
| White | 1 | 4 | — | 5 |
| More than one race | 0 | 0 | — | 0 |
| Unknown or Not Reported | 0 | 2 | — | 2 |
| Region of Enrollment(participants) | Assigned to Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹) | Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹) | Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹) | Total |
|---|---|---|---|---|
| United States | 1 | 7 | — | 8 |
| Tumor Type(Participants) | Assigned to Dose Level 1 (Target 5 × 10⁹ TCR+ Cells; Range 1 to <10 × 10⁹) | Assigned Dose Level 2 (Target 40 × 10⁹ TCR+ Cells; Range 10 to <70 × 10⁹) | Assigned Dose Level 3 (Target 100 × 10⁹ TCR+ Cells; Range 70 to 150 × 10⁹) | Total |
|---|---|---|---|---|
| Colorectal | 0 | 4 | 0 | 4 |
| Pancreatic | 0 | 3 | 0 | 3 |
| Non-small cell lung cancer | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2022 to primary completion in Sep 2023, 17 months.
Results were first posted in Nov 2025, 2 years 1 month after primary completion.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Aug 2023 → Sep 2023 and completion Aug 2023 → Oct 2023.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Sponsor halted enrollment on 14 Aug 2023 for business reasons after a Board review of funding needs and permanently discontinued TCR-T cell manufacturing. The study was not stopped for safety reasons.
Morelli MP, Negrao MV, Collinson-Pautz MR, et al. Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by soli…
Sponsor halted enrollment on 14 Aug 2023 for business reasons after a Board review of funding needs and permanently discontinued TCR-T cell manufacturing. The study was not stopped for safety reasons.
Morelli MP, Negrao MV, Collinson-Pautz MR, et al. Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by soli…
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aldesleukin